01 — Evidence
Evidence Summary
Apigenin has a broad laboratory and animal record — dozens of cell studies, and reduced tumour growth reproduced across several animal cancers — but very little human evidence. A large pharmacokinetic gap separates the two: oral doses reach only a fraction of the concentrations active in the lab. The tiers below set out, in turn, what the human, animal, and cell studies each found.
Human
Clinical Record
One confounded cohort; no anti-tumour trial
No completed human trial shows apigenin shrinks a tumour or extends survival. The only cancer-outcome data pairs apigenin with another flavonoid, so it can't be read as apigenin acting alone.
- Lower colorectal-neoplasia recurrence in a small non-randomised cohort — but apigenin was combined with EGCG
- A scaled-up prevention trial was registered, then suspended without results
- A human absorption study completed without posted results; a cancer-centre feeding study was withdrawn
Animal
Preclinical Signal
Tumour-directed activity across many cancers
In animal models apigenin reduced tumour growth, blood-vessel growth, and metastasis across several cancers. Most used injection or higher oral doses; one prostate-prevention model used low oral doses.
- Reduced blood-vessel growth and tumour size in lung, esophageal, and liver models
- Low oral doses abolished metastasis and improved survival in a prostate-prevention model
- Extended survival in a mesothelioma model and attenuated a leukaemia model
In Vitro
Cell Model Data
Broad mechanisms; concentration caveat
Across many cancer cell lines apigenin suppresses survival signalling, blocks glucose use, and triggers programmed death — but usually at concentrations far above what oral doses reach in the blood.
- Suppressed PI3K–AKT–mTOR, STAT3, and Wnt/β-catenin signalling across several cancers
- Lowered glucose transporters and glycolysis in pancreatic and breast cells
- Triggered mitochondrial apoptosis, at concentrations well above achievable blood levels
Human
Clinical Record
No completed human trial shows apigenin shrinks a tumour or extends survival. The single cancer-outcome dataset is a small, non-randomised cohort in which apigenin was taken together with EGCG, so the benefit cannot be attributed to apigenin alone.[2] Underneath that, the human pharmacokinetic data explain why translation is hard: a large dietary dose lifted plasma apigenin to only about 0.13 µM.[1]
Continue reading — full research detail+
The one published human cancer-outcome study was a non-randomised cohort of 87 patients after colorectal cancer resection or polypectomy, of whom 31 elected to take a combination providing 20 mg apigenin plus 20 mg EGCG daily and 56 served as matched untreated controls, over 3–4 years of surveillance. In the resected-colorectal-cancer subgroup followed by surveillance colonoscopy (14 treated versus 15 controls), combined neoplasia recurrence was 7% versus 47% (P=0.027).[2] This is a genuine signal, but the intervention was a fixed apigenin-plus-EGCG combination, the design was non-randomised, surveillance colonoscopy was not equally complete across the groups (the authors' own caveat), and the subgroup was small — so it cannot be read as an apigenin effect. A registered phase 2 scale-up of this concept was suspended without results, and a cancer-centre celery-feeding feasibility study was withdrawn with no enrolment.[25,27]
The pharmacokinetic context is the load-bearing fact. In an older controlled human study, a large apiin-rich parsley dose (about 66 µmol apigenin) produced a mean plasma peak of only 127 nmol/L (~0.13 µM) at around 7 hours, with just 0.22% of the dose recovered in urine.[1] A more recent metabolite-resolved human study (registered as NCT03526081,[26] later published[41]) confirmed that free apigenin is very poorly absorbed and that its uptake depends heavily on the food form — urinary recovery of apigenin metabolites was equivalent to about 0.5% of intake for pure apigenin, ~11% from a parsley drink, and ~34% from chamomile tea.[41] Either way, because most of apigenin's cell-model effects require single-to-tens-of-micromolar concentrations, this low, conjugate-dominated exposure is the gap every laboratory finding has to be read against.
Signal maturity: there is no controlled human anti-tumour evidence for apigenin. The single cohort is small, non-randomised, and used a fixed apigenin+EGCG combination; the registered scale-up stalled. A wider pattern is worth flagging: apigenin's two most treatment-relevant datapoints — this colorectal-recurrence cohort and a separate rat study of apigenin's effect on paclitaxel levels (see Co-Dosing Considerations) — each dosed it in a fixed combination, with EGCG and with rutin respectively, so neither isolates what apigenin itself contributed. The human data establish low oral exposure, not efficacy.
Animal
Preclinical Signal
In living animals apigenin reduced tumour growth, angiogenesis, and metastasis across esophageal, lung, breast, cervical, hepatocellular, prostate, leukaemia and mesothelioma systems — most by injection or higher oral doses, with clear low-dose oral efficacy shown in a prostate-prevention model.[28,14]
Continue reading — full research detail+
The clearest oral evidence is the transgenic-adenocarcinoma-of-mouse-prostate (TRAMP) prevention model, where one research programme reproduced several distinct mechanisms at the same low oral dose (20–50 µg per mouse, roughly 1–2 mg/kg). Apigenin decreased prostate tumour volume, completely abolished distant metastases to lymph nodes, lungs and liver, and — with continuous intake to 50 weeks — improved overall survival, while directly in tumour tissue it blocked β-catenin signalling,[28] suppressed PI3K/Akt/FoxO signalling,[42] inhibited NF-κB/IKK with lower VEGF, uPA and MMP-2/9,[29,43] and inhibited class-I HDACs.[44] This is the one setting where an oral dose in the plausible range produced a strong in-vivo effect, though TRAMP is an autochthonous prevention model rather than treatment of an established tumour.
The strongest survival signal in a treatment setting used a non-oral route: in a mesothelioma model, intraperitoneal apigenin (20 mg/kg/week) extended median survival to 12 versus 5.5 weeks.[14] Across other cancers, apigenin reduced tumour angiogenesis and growth in lung, esophageal and hepatocellular xenografts,[3,5,6,8] inhibited a breast (4T1) xenograft with reduced glycolysis,[32] and attenuated a leukaemia (U937) xenograft.[30]
Signal maturity: consistent and multi-cancer, with genuine in-vivo corroboration. A meta-analysis of 25 animal studies found pooled reductions in tumour volume, weight, number and load, but reported funnel-plot asymmetry suggesting publication bias — so the apparent consistency likely overstates the certainty of the effect.[45] Most models used injection or higher oral doses than a supplement reaches, the strongest oral evidence (prostate) is a prevention model, and much of that oral work comes from a single research lineage — several mechanistic papers from one programme are not independent replication.
In Vitro
Cell Model Data
Across many cancer cell lines apigenin suppresses pro-survival signalling, blocks glucose metabolism, and drives programmed death — converging on PI3K–AKT–mTOR, STAT3, Wnt/β-catenin, cyclin B1/CDK1 and Bax/Bcl-2 — but at roughly 5–60 µM, far above the ~0.13 µM plasma peak measured in humans.[1]
Continue reading — full research detail+
The mechanistic breadth is real. Apigenin down-regulated PI3K–AKT–mTOR in cervical and hepatocellular cells,[9,10] suppressed STAT3 in lung cells,[11] drove autophagy–lysosomal degradation of β-catenin in colorectal cells,[13] lowered the GLUT-1 transporter and glycolytic enzymes in pancreatic and breast cells,[31,32] and induced mitochondrial apoptosis (raised Bax/Bcl-2, active caspase-9) in mesothelioma and myeloma lines.[14,15]
The recurring caveat is concentration. The effective concentrations cluster at roughly 5–60 µM — esophageal growth inhibition at 4.8–9.3 µM,[3] multiple myeloma at 10.7 µM,[15] cervical at about 50 µM,[9] mesothelioma at 34–57 µM,[14] and colorectal at 30–61 µM.[13] Measured against the ~0.13 µM human plasma peak,[1] that is a 40-to-500-fold gap, and it is the single most important qualifier on every cytotoxic claim on this page.
Signal maturity: the mechanistic case is broad and reproducible across cancer types, but almost entirely at concentrations above achievable human plasma. The in-vitro data establish mechanism, not reachable exposure.
Advertisement
02 — Pathways
Pathway Interaction Profile
Apigenin engages a broad set of tumour-relevant pathways, grouped below by the functional role each supports. The pattern is consistent throughout: real, often animal-corroborated mechanisms, read against a pharmacokinetic gap that holds every tumour-directed role to partial. Further down, a separate set of pathways covers host resilience — normal-tissue protection during cancer treatment, all preclinical.
Apigenin's Contain classification rests on reported suppression of the inflammatory IL-6 signalling a tumour uses to prime a supportive niche, the blood-vessel-growth signalling it needs to feed a new site, and the invasion machinery that lets cells break away — corroborated in several animal models, though at exposures above what oral dosing reaches in humans.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
NF-κB / TNF-α / IL-6 inflammatory axis
Apigenin was characterised as a small-molecule inhibitor of IL-6 transcription: in esophageal-carcinoma cells it cut IL-6 protein by up to 89% and IL-6-promoter activity by around half, with parallel reductions in VEGF, and an in-vivo xenograft showing dose-dependent drops in tumour weight, microvessel density and tumour IL-6.[3] In triple-negative breast cancer it lowered IL-6 and, through IL-6 suppression, reduced migration and invasion while slowing an oral-dosed xenograft.[4] The axis also has a low-dose oral in-vivo anchor: in the prostate (TRAMP) model, oral apigenin inhibited IKK activation, stabilised IκBα and reduced NF-κB DNA binding, lowering the NF-κB-controlled genes cyclin D1, COX-2, Bcl-2/Bcl-xL and VEGF, with abolished metastasis.[43]
Angiogenesis / VEGF / HIF-1α
The most-replicated finding on the page. Apigenin lowered HIF-1α and VEGF with reduced in-vivo vascularity in lung cancer — decreasing VEGF transcription via the HIF-1 binding site in an A549 nude-mouse model[5] and reducing microvessel density in non-small-cell lung xenografts[6] — reduced tumour angiogenesis in a chick chorioallantoic-membrane assay,[7] and blocked hepatocellular-carcinoma angiogenesis by hindering VEGF-carrying microvesicle release.[8] In the low-dose oral prostate (TRAMP) model it reduced VEGF, uPA and MMP-2/9 alongside a complete absence of metastasis.[29]
Prevent Tumour Cell Shedding
Research concerning invasion and escape from existing lesions (EMT and ECM breach).
EMT & metastatic invasion
In triple-negative breast cancer cells, apigenin reduced migration and invasion and lowered the EMT markers Snail and N-cadherin, with IL-6 knockdown reproducing the shift toward a less invasive state.[4] Oral apigenin also abolished distant metastases (lymph node, lung, liver) in the TRAMP prostate model, raising E-cadherin and reducing matrix-degrading uPA and MMP-2/9.[28,29] An earlier study that reported apigenin suppressing colon-cancer invasion through an NF-κB/Snail mechanism was later retracted by its journal,[52] so it is not relied on here; the invasion evidence rests on the non-retracted breast and prostate studies above.
Apigenin's Starve classification rests on reported suppression of the glucose metabolism cancer cells depend on — lowering glucose uptake, the GLUT-1 transporter, and glycolytic enzymes — with one in-vivo corroboration, at concentrations above achievable oral exposure.
Glucose Axis Pressure
Research concerning glycolytic ATP production and glycolytic intermediates used by cancer cells.
Aerobic glycolysis (Warburg effect)
Apigenin suppressed tumour glucose metabolism in two settings. In pancreatic-cancer cells it inhibited glucose uptake and down-regulated the GLUT-1 transporter at both the messenger-RNA and protein level, an effect reproduced by PI3K inhibitors — placing it on the PI3K/Akt axis.[31] In triple-negative breast cancer it lowered the glycolytic machinery — PKM2, GLUT1, HK2 and LDHA — with reduced lactate and ATP output, and those glycolysis-related proteins were regulated in a 4T1 xenograft in vivo.[32] The effective concentrations exceed achievable oral plasma exposure.
Apigenin's Weaken classification is its broadest: reported suppression of the pro-survival signalling and cell-cycle machinery tumours use to keep dividing, across several named pathways and cancer types, with animal corroboration but a recurring concentration gap.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
PI3K–AKT–mTOR (signaling)
The strongest translational anchor is oral and low-dose: in the prostate (TRAMP) model, oral apigenin suppressed Akt and FoxO3a phosphorylation, restored nuclear FoxO3a, raised the pro-apoptotic proteins BIM and p27, and abolished metastasis — demonstrating PI3K/Akt inhibition directly in tumour tissue rather than only at high cell-culture concentrations.[42] In cervical-cancer cells apigenin also down-regulated PI3K, AKT and mTOR, with a C33A xenograft showing reduced tumour volume (from about 666 to 271 mm³) and lower Ki-67 and Bcl-2,[9] and in hepatocellular carcinoma it inhibited the same axis to induce apoptosis and autophagy in vivo.[10] The cell-model effective concentrations (around 50 µM) still sit well above achievable oral plasma levels.
JAK/STAT (STAT3)
In KRAS-mutant lung-cancer models, apigenin suppressed STAT3 phosphorylation — lowering inducible PD-L1, inhibiting proliferation and inducing apoptosis — and showed antitumour activity in a genetically-engineered KRAS-mutant mouse model, with PD-1 blockade enhancing the effect.[11] The study tested luteolin as the lead compound alongside apigenin; the apigenin-specific in-vivo results are attributed to apigenin, with luteolin the more potent congener.
Cell cycle checkpoints (CDK4/6–RB–E2F, G1/S, G2/M)
Apigenin induced G2/M arrest in cervical-cancer cells by lowering CDK1, CDC25c and cyclin B1 while raising the checkpoint brake p21, with reduced cyclin B1 confirmed on in-vivo tissue staining.[9] The mechanism engaged is the cyclin B1/CDK1 G2/M axis specifically, within this checkpoint pathway's broader scope.
Wnt / β-catenin
In colorectal-cancer cells, apigenin drove autophagy–lysosomal degradation of β-catenin, reducing β-catenin/TCF transcriptional activity, with autophagy inhibitors rescuing β-catenin accumulation to confirm the route.[13] This axis carries the page's strongest oral in-vivo anchor: low-dose oral apigenin blocked β-catenin signalling in the TRAMP prostate model — raising E-cadherin and lowering nuclear β-catenin, c-Myc and cyclin D1 — with reduced tumour volume, abolished metastasis, and improved survival.[28]
Apigenin's Attack classification rests on intrinsic mitochondrial apoptosis — its core direct-killing mechanism — with the page's clearest in-vivo survival signal and an independent replication, but at concentrations above achievable oral exposure and, for the survival result, a non-oral route.
Direct Tumour-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
In malignant mesothelioma, apigenin raised the Bax/Bcl-2 ratio, increased p53, activated caspase-9, and — given intraperitoneally — extended median survival to 12 versus 5.5 weeks, with in-vitro killing concentrations of 34–57 µM.[14] An independent leukaemia study reproduced the mechanism: in U937 cells apigenin inactivated Akt with JNK activation, Mcl-1/Bcl-2 down-regulation and cytochrome-c release, and attenuated a U937 xenograft in vivo.[30] Mitochondrial apoptosis with Bcl-2 down-regulation was also seen in the cervical model.[9] The survival benefit used intraperitoneal dosing above achievable oral exposure.
Ferroptosis (execution / cell death)
A second, more recent regulated-death mechanism. In multiple-myeloma cells apigenin induced ferroptosis alongside apoptosis (a ferroptosis-inhibitor-attenuable component),[15,16] and in triple-negative breast cancer it lowered the ferroptosis defences GPX4 and SLC7A11 and raised iron, malondialdehyde and reactive oxygen species, with ferroptosis-related proteins regulated in a 4T1 xenograft.[32] Apoptosis remains the dominant, best-corroborated death mode, and the direction is context-dependent: in a non-cancer kidney model apigenin instead inhibited ferroptosis,[20] so this is a genuine but not reliable tumour-ferroptosis lever.
Apigenin's Protect classification is preclinical throughout. There is no controlled human host-protection evidence attributable to apigenin, but a broad and consistent set of animal studies report protection of normal tissue against specific cancer treatments — spanning the heart, kidney, liver, peripheral nerves, and mucosa.
Oncology Host-Status
Chemoprevention of neoplasia recurrence (confounded) — the only human cancer-outcome dataset is a non-randomised cohort in which apigenin was taken together with EGCG; in the resected-colorectal-cancer subgroup, combined neoplasia recurrence was lower than in untreated controls, detailed under Evidence Summary above.[2] Because the intervention was a fixed apigenin-plus-EGCG combination in a small, non-randomised group, it cannot be attributed to apigenin alone, and a registered phase 2 scale-up was suspended without results.[25]
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Anthracycline (doxorubicin) cardioprotection
In two independent in-vivo doxorubicin models, oral apigenin restored cardiac function and reduced myocardial injury, fibrosis and oxidative stress. A mouse study tied the protection causally to the Sirt1/Atf5 mitochondrial-unfolded-protein-response pathway — both Sirt1 knockout and blockade of that response abolished the benefit[33] — and a rat study found it nitric-oxide-dependent with restored connexin-43.[34] These experiments establish normal-tissue protection but do not establish treatment selectivity: whether the same intervention preserves doxorubicin's anticancer efficacy was not tested in a tumour-bearing model, and there are no human data.
Cisplatin renal and hepatic protection
Among seven flavonoids compared in vivo, apigenin gave the greatest reduction of cisplatin-induced liver and kidney toxicity, lowering kidney inflammation and inhibiting p38/ERK/JNK signalling,[17] and it protected against cisplatin nephrotoxicity in kidney cells in vitro.[18] This is preclinical normal-tissue protection against a specific chemotherapeutic; whether it preserves cisplatin's anticancer efficacy was not tested simultaneously, so treatment selectivity is unknown, and there are no human data.
Radiation and peripheral-neuropathy protection
Oral apigenin before whole-body irradiation mitigated radiation damage to mouse spermatogenesis on histology,[19] and in a paclitaxel chemotherapy-induced peripheral-neuropathy model it reduced pain behaviours and spinal inflammatory signals (TNF-α, IL-1β) through NRF2/ARE activation and a shift in microglial state.[35] Both are preclinical normal-tissue protection findings.
GI Integrity & Microbiome
Research concerning gut-barrier integrity, microbiome composition, and host immune regulation.
Chemotherapy oral mucositis
In a 5-fluorouracil oral-mucositis hamster pilot, potassium apigenin — a locally-applied salt at the mucosal surface, not a swallowed systemic supplement — reduced inflammatory-cell counts at days 7 and 10 and accelerated ulcer healing versus control.[36] This is a single small preclinical pilot; separately, the human chamomile mucositis trials use whole extract and are not apigenin-attributable.
Block Seeding & Niche Formation
Research concerning formation of supportive pre-metastatic niches at distant sites.
Apigenin lowered the blood-vessel-growth signals HIF-1α and VEGF and reduced tumour vascularity across several animal cancer models — the most consistently replicated finding for this compound.
Glucose Axis Pressure
Research concerning glycolytic ATP production and glycolytic intermediates used by cancer cells.
Aerobic glycolysis (Warburg effect)
Apigenin lowered glucose uptake, the GLUT-1 transporter, and glycolytic enzymes in pancreatic and breast cancer cells, with one breast xenograft corroborating the effect in a live animal.
Expansion Suppression
Research concerning proliferation, cell-cycle progression, and the capacity of lesions to add durable mass.
Apigenin drove degradation of β-catenin in colorectal cells and, in a low-dose oral prostate model, blocked β-catenin signalling with abolished metastasis and improved survival — the page's strongest oral in-vivo result.
Direct Tumour-Directed Killing
Research concerning regulated tumour-cell death (apoptosis, ferroptosis, necroptosis).
Intrinsic apoptosis (mitochondrial / Bcl-2)
Apigenin triggered mitochondrial apoptosis in mesothelioma and leukaemia models, extending survival in one and shrinking a xenograft in the other. Evidence is preclinical — concentration limitations apply.
Other Organ-System Reserve
Research concerning renal, cardiac, pulmonary, and other non-hepatic organ reserve under stress.
Anthracycline cardioprotection
Oral apigenin protected the heart from doxorubicin toxicity in two animal models, with a causally-confirmed mitochondrial-stress-response mechanism — preclinical host protection, no human data.
Advertisement
03 — Pharmacokinetics
Pharmacokinetics and Administration
Apigenin's pharmacokinetics are the reason its broad laboratory activity has not translated. It is poorly absorbed, rapidly conjugated, and reaches only sub-micromolar plasma concentrations — well below the levels active in cell studies. Formulation research exists, but none of it underlies apigenin's human cancer-relevant evidence.
Absorption
Apigenin is poorly water-soluble and heavily metabolised on first pass. A large dietary dose lifted human plasma to a peak of only ~0.13 µM, reached late and cleared within about a day, with circulating apigenin mostly present as conjugates.
The Concentration Gap
Most of apigenin's antiproliferative effects in a dish need 5–60 µM — roughly 40 to 500× the plasma peak achievable with oral dosing. This gap is the single most important qualifier on every laboratory finding.
Clinical Dose Context
Dietary intake is a few milligrams a day; supplements provide tens to hundreds of milligrams. The only human cancer-outcome study used 20 mg/day — combined with EGCG, not apigenin alone.
Formulation Effects
Enhanced-delivery forms (nanoparticles, phospholipid and micellar carriers) are being researched, but none was used in apigenin's human cancer-relevant evidence, so a bioavailability gain can't be assumed to produce an oncology outcome.
Metabolism
Apigenin undergoes rapid glucuronidation (via UGT1A9) and sulfation in gut and liver; conjugated metabolites dominate the circulation, with enterohepatic recycling prolonging low-level exposure.
Co-Dosing Considerations
Apigenin inhibits the BCRP and P-glycoprotein efflux pumps and CYP3A4 — all involved in clearing oncology drugs — so combining it with active treatment is a treating-team decision.
Absorption
Apigenin's low oral bioavailability is the defining pharmacokinetic fact for this compound, and how much is absorbed depends strongly on the chemical form. In an older controlled human study, eleven healthy adults given a large apiin-rich parsley dose (about 66 µmol apigenin) reached a mean plasma peak of just 127 nmol/L — roughly 0.13 µM — at around 7 hours, with the level below detection by 28 hours and only 0.22% of the dose recovered in urine.[1] The reason is rapid first-pass conjugation: after absorption apigenin is quickly turned into glucuronide and sulfate metabolites in the gut wall and liver, so circulating free apigenin stays very low.[22,23] A more recent metabolite-resolved human study sharpened this: free apigenin aglycone was very poorly absorbed (urinary metabolites equivalent to about 0.5% of intake), but apigenin glycosides behaved quite differently — a parsley drink gave recovery equivalent to about 11% of intake and chamomile tea about 34%, with three conjugates (apigenin-4′-glucuronide, apigenin-7-glucuronide and apigenin-7-sulfate) dominating.[41] So the defining fact is a pattern, not one number: low, conjugate-dominated exposure whose magnitude varies several-fold with the source.
The Concentration Gap
This gap has three parts, not one. First, concentration: almost every antiproliferative and pro-apoptotic effect apigenin shows in cell studies needs 5–60 µM, while measured human systemic exposure sits in the low-nanomolar-to-sub-micromolar range. Second, chemical form: those cell studies add free apigenin directly to cells, whereas human circulation after oral intake is dominated by glucuronide and sulfate conjugates, not a sustained free-aglycone pool.[41] Third, compartment: a plasma concentration is not the same as unbound intracellular or tumour-tissue exposure. So the fold-differences in the table below are a rough benchmark, not a precise pharmacological equivalence — the translational gap concerns concentration and chemical species and compartment together, and tumour exposure to biologically available free apigenin has not been established. The animal studies that do report tumour-directed activity used injection or higher oral doses, the low-dose oral prostate-prevention model excepted.
| Benchmark | Concentration | Interpretation |
|---|---|---|
| Human plasma peak after a large dietary dose | ~0.13 µM | The measured achievable exposure in people — mostly conjugated and short-lived[1] |
| Esophageal-cell growth inhibition (IC50) | 4.8–9.3 µM | Among the lowest active concentrations reported — still roughly 40× the plasma peak[3] |
| Multiple-myeloma killing (IC50) | 10.7 µM | A blood-cancer line, around 80× the plasma peak[15] |
| Colorectal β-catenin degradation (IC50) | 30–61 µM | The Wnt/β-catenin effect needs hundreds of times the plasma peak[13] |
| Mesothelioma killing (IC50) | 34–57 µM | The in-vitro side of the survival-extending model, far above achievable plasma[14] |
Clinical Dose Context
Dietary apigenin intake is low — single-digit milligrams per day — while retail supplements commonly deliver tens to a few hundred milligrams. The only human cancer-outcome study used 20 mg/day of apigenin, and critically it was given together with 20 mg/day of EGCG, so the exposure cannot be tied to apigenin alone.[2] No oncology dosing framework defines a target exposure for apigenin, and the human pharmacokinetic data show that ordinary oral doses do not reach the concentrations active in cell studies.[1]
Formulation Effects
Apigenin's poor solubility has prompted enhanced-delivery research — nanoparticle, phospholipid, and micellar carriers — but none of this compound's human cancer-relevant evidence used an enhanced formulation. The cohort study used unformulated apigenin with EGCG,[2] and the animal studies used simple aqueous or injected preparations. No enhanced-delivery form has been tested against a cancer-relevant human endpoint, so a demonstrated bioavailability advantage cannot be assumed to translate into an oncology outcome.
Metabolism
Apigenin undergoes rapid phase-II conjugation — glucuronidation and sulfation in the intestinal wall and liver, UGT1A9 among the glucuronidating enzymes (silencing UGT1A9 cut apigenin-glucuronide output by more than three-quarters).[40] The human study confirmed the result directly, identifying apigenin-4′-glucuronide, apigenin-7-glucuronide and apigenin-7-sulfate as the circulating and excreted metabolites, so conjugates dominate rather than the free aglycone.[41] Preclinical disposition studies add the mechanism: extrahepatically-formed glucuronides are excreted directly into bile, supporting enteric/enterohepatic recycling and the low systemic bioavailability,[22,23] with the apigenin glucuronide itself effluxed by the BCRP transporter[40] — though the quantitative importance of that recycling in humans is not well established. The biological activity of these circulating conjugates within tumour tissue is not established.
Co-Dosing Considerations
No human pharmacokinetic drug-interaction study for apigenin with a specific oncology drug is available. The rows below rest on in vitro human-transporter data and animal studies, and each is flagged by the most cautious guidance that evidence supports.
Discuss whether to combine, separate, or avoid apigenin and a medication with your treating oncology team or physician.
| Flag | Interaction |
|---|---|
| Caution | Medicines cleared by the BCRP/ABCG2 or P-glycoprotein efflux pumps — including mitoxantrone, topotecan, irinotecan (SN-38), methotrexate and paclitaxel — warrant clinician review. Apigenin is a potent BCRP inhibitor in a human transporter assay (inhibition constant below 0.1 µM) and a P-glycoprotein inhibitor, and raised chemotherapy-substrate accumulation and cytotoxicity in resistant tumour cells; co-dosed with rutin it raised oral paclitaxel blood levels in rats. The effect is two-sided — it could raise a drug's systemic exposure, or increase drug retention within a tumour and reverse resistance — and no human interaction magnitude has been demonstrated.[37,38,39,51] |
| Caution | Medicines cleared by CYP3A4 — which include several chemotherapy agents — warrant similar review. Flavones with apigenin's hydroxylation pattern significantly inhibited CYP3A in human liver microsomes, an effect also seen for apigenin in intestinal cells. This is laboratory data; no human interaction magnitude has been demonstrated.[50,24] |
Advertisement
04 — Onset & Washout
Onset and Washout
Apigenin's plasma clock and any tissue-level effect are two different things: circulating apigenin peaks late and low and clears within about a day, while the cell and animal effects developed over sustained exposure and the one human outcome was measured over years of daily dosing.
Immediate Onset
After a single oral dose, plasma apigenin rises slowly to a low peak and falls below detection within about a day — this describes blood concentration only, not how long any biological effect lasts.
Steady State
No repeated-dose human study establishes steady-state free-apigenin levels. Because circulating apigenin is largely conjugated and short-lived, a single dose does not represent steady-state tissue exposure.
Accumulated Effect
The cell and animal efficacy studies developed their effects over continuous exposure, and the one human cancer-outcome dataset measured recurrence over 3–4 years of daily use. The human PK studies, by contrast, were single-dose — the two clocks measure different things.
Dosing Pattern in Studies
Every oncology-outcome and tumour-efficacy study used repeated dosing (the human PK studies were single-dose). That is the regimen apigenin's effects have been studied under — not proof that a pulsed schedule has been tested and shown not to work.
Washout
How long apigenin's influence can take to clear before it stops being a relevant factor for co-administered medications.
No clinically validated washout period exists. Plasma apigenin clears within about a day, but the transporter- and enzyme-inhibition signals that matter for drug co-dosing come from laboratory studies, and their duration in the body has not been measured — so a washout time cannot be calculated from plasma clearance alone.
Two Distinct Clocks
Apigenin's timeline splits into two genuinely different layers: how quickly it appears in and leaves the blood, and how long its downstream effects take to develop. The two are not directly connected by any measurement available here.
Clock A — Measured Plasma Exposure — is low and short-lived, and its timing depends on the source form. An older study using a large apiin-rich parsley dose reached a plasma peak of only about 0.13 µM at roughly 7 hours, falling below detection by 28 hours,[1] while a metabolite-resolved study found the peak occurred earlier from chamomile (~2 h, upper-gut absorption) than from a parsley drink (~4 h) or dried parsley (~6 h).[41] Because circulating apigenin is dominated by conjugated metabolites,[22,23,41] plasma clearance does not establish when target engagement in a tissue begins or ends.
Clock B — Downstream Effect — is what the biological studies actually measured, and it runs much longer. The cell and animal effects developed over sustained exposure, and the one human cancer-outcome dataset recorded reduced neoplasia recurrence over 3–4 years of continuous daily apigenin-plus-EGCG dosing.[2] No oncology study established the biological effect of intermittent versus continuous dosing, and none measured how Clock A's plasma exposure connects mechanistically to Clock B's outcome — the human single-dose PK studies and the repeated-dose outcome cohort simply measure different things.
Steady State and Accumulation
Not established. No repeated-dose human study confirms steady-state free-apigenin levels, accumulation, or continuous target engagement. What the studies establish is more limited: every studied regimen used repeated daily dosing. That supports daily administration as the studied regimen — it does not prove daily dosing is biologically necessary to sustain a pathway-level effect, and it says nothing about whether tissue concentrations ever reach the levels active in cell studies (see The Concentration Gap under Pharmacokinetics and Administration).
Dosing Pattern in Studies
The efficacy studies in this profile — the human cohort and the animal models — used repeated, continuous or repeated dosing: 20 mg/day apigenin (with EGCG) over 3–4 years in the human cohort,[2] and daily or weekly dosing over the experimental period in the animal work.[9,14] The human pharmacokinetic work, separately, was single-dose. No study tested intermittent versus continuous dosing against a biological endpoint, so apigenin is best described as studied under daily, continuous dosing for the applications it has actually been tested for — not because pulsed dosing has been shown to fail, but because it has not been tested.
Washout
No clinically validated apigenin washout period has been established. Plasma apigenin clears within about a day,[1] but the interactions that matter for co-dosing — inhibition of the BCRP and P-glycoprotein efflux pumps and of CYP3A4 — are documented in laboratory systems,[37,39,24] and how long that inhibition would persist in the body has not been measured. A parent compound's plasma half-life cannot be used to calculate an enzyme- or transporter-interaction washout, since that duration can depend on active metabolites, intracellular retention, whether inhibition is reversible or time-dependent, and repeated dosing — none of which has been characterised for apigenin. A washout interval should not be calculated from plasma clearance alone, and none is recommended here.
Advertisement
05 — Safety
Safety Profile
The most important safety point for a cancer audience is not an organ-toxicity signal but two things the research raises specifically for tumour biology: apigenin behaves as a phytoestrogen that can stimulate estrogen-receptor-positive breast-cancer cells at low concentrations, and it inhibits drug-clearing transporters and enzymes. Human safety data for isolated apigenin, meanwhile, are sparse rather than reassuring.
Estrogen-receptor activity — apigenin is a phytoestrogen and, at low concentrations, stimulated the growth of estrogen-receptor-positive breast-cancer cells in the laboratory; it cannot be assumed neutral in ER-positive breast cancer.
Sparse human safety data — no dedicated human safety or toxicity study of isolated apigenin was identified, so long-term, cancer-stage tolerability is undefined rather than proven safe.
Drug-clearance interactions — apigenin inhibits drug-clearing transporters and enzymes in laboratory studies, which matters when it is combined with oncology drugs; see Co-Dosing Considerations.
Pregnancy — dedicated reproductive-safety data for supplemental apigenin weren't identified, and apigenin has measurable estrogen-receptor activity in animals; use during pregnancy should be reviewed by a clinician.
Oncology-Specific Consideration: Estrogen-Receptor Activity
Apigenin is a phytoestrogen and is not uniformly anti-cancer in hormone-sensitive tissue. It stimulated proliferation of estrogen-receptor-alpha-positive breast-cancer cells (MCF-7, T47D) but not an ER-negative line, consistent with ER-alpha activation,[46] and the effect is dose-dependent and directionally split: at about 1 µM apigenin stimulated MCF-7 growth and ER-alpha transcriptional activity, while above about 10 µM it inhibited growth and even synergised with tamoxifen or fulvestrant.[47] In animals it behaved as a partial estrogen-receptor agonist with context-dependent estrogenic and anti-estrogenic activity.[48] This matters here because the page's own pharmacokinetics argue that low-micromolar and sub-micromolar exposure is the achievable range — the same range where the breast-cancer model showed a growth-stimulatory effect. This is preclinical and does not establish clinical harm, but apigenin cannot currently be assumed neutral in ER-positive breast cancer. It is not evidence that apigenin interferes with tamoxifen — the tamoxifen-antagonism finding in that literature concerned a different flavone (genistein), and apigenin combined with tamoxifen at higher concentrations was synergistic — so the honest message is dose-dependent endocrine uncertainty, not a specific drug conflict.
Adverse Effects and Tolerability
Human safety data for isolated supplemental apigenin are sparse. Dietary exposure is longstanding, and the small short-term human studies available — a 7-day parsley intervention providing about 84 mg/day apigenin (with plasma apigenin unmeasurable and no adverse hemostatic signal)[49] and the small metabolism-focused absorption study[41] — have not generated a prominent toxicity signal, but they are too small and too short to establish the safety profile of high-milligram supplemental exposure, long-term use, or use during cancer therapy. No dedicated human apigenin safety study and no LiverTox drug-induced-liver-injury monograph exist. The frequently-repeated "sedative" effect is better established in experimental apigenin and chamomile pharmacology than in clinical purified-apigenin supplementation, and should not be read as a documented supplement adverse-effect rate.
Drug-Handling Interactions
The other consideration that weighs more for a cancer audience is drug handling, and it goes beyond ordinary CYP metabolism. In laboratory systems apigenin inhibits the BCRP and P-glycoprotein efflux pumps as well as CYP3A4 — between them these clear a broad list of oncology drugs, including mitoxantrone, topotecan, irinotecan, methotrexate and paclitaxel — and the transporter effect is two-sided, since it could raise a drug's systemic exposure or instead increase drug retention inside a tumour.[37,51,50] These are potential drug-interaction effects, not adverse effects of apigenin on the patient; each is set out with its flag in the Co-Dosing Considerations table under Pharmacokinetics and Administration above. No human interaction has been demonstrated, and none is restated as a second table here.
Pregnancy and Reproductive Safety
Apigenin is a normal dietary constituent, but dedicated human pregnancy-safety data for supplemental doses were not identified in the literature reviewed. Categorical claims that no reproductive-toxicology data exist anywhere are difficult to support with full confidence, so this is stated as an absence in the literature reviewed here rather than a confirmed absence across all research. Avoidance during pregnancy is prudent unless use is specifically reviewed by a qualified clinician.
06 — Sourcing
Sourcing Guide
Because apigenin is poorly absorbed, formulation and dose are the biggest factors in whether a product delivers a meaningful exposure — though, as the research above makes clear, even enhanced-delivery forms have not been tested against a cancer-relevant human endpoint. Purity, characterization, and which plant the extract is drawn from matter too — apigenin is isolated from several plants, so the botanical source varies by product. Our Sourcing Guide offers a curated list of products available on the retail market we found to answer those concerns.
Apigenin Sourcing Guide07 — Literature
References
Last reviewed: August 2026